INTRAVENOUS VERNAKALANT FOR THE TREATMENT OF NEW-ONSET ATRIAL FIBRILLATION IN THE EMERGENCY DEPARTMENT
2019
Vernakalant is a novel antiarrhythmic agent with a preferential effect on atrial tissue and limited action on ventricular tissue. Intravenous vernakalant effectively converts recent onset atrial fibrillation; conversion is usually achieved quickly with a short half-life and allows early hospital
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI